1. INTRODUCTION:

Lead identification is a pivotal stage in the drug discovery process, wherein compounds with the potential to modulate a biological target are identified from large chemical libraries. Traditionally, this process has relied on high-throughput screening (HTS) methods, which, while effective, are often expensive, time-consuming, and require significant resources. The advent of AI has introduced innovative computational techniques that enhance the efficiency and accuracy of this process, transforming the landscape of lead identification^1,2.

AI's capabilities in processing large datasets, recognizing patterns, and making predictions based on complex inputs have enabled its application across various domains, including drug discovery³. Specifically, in lead identification, AI-driven approaches are now capable of predicting biological activity, optimizing molecular structures, and even generating new compounds with desired properties. This review discusses the key AI methodologies used in lead identification, their applications, challenges, and future directions.

2. AI Methodologies in Lead Identification:

AI in lead identification employs various computational techniques, including machine learning (ML), deep learning (DL), natural language processing (NLP), and reinforcement learning (RL). These methodologies have distinct roles in enhancing different aspects of the lead identification process.

2.1 Machine Learning in Lead Identification:

Machine learning, a subset of AI, uses algorithms to learn from data and make predictions or decisions without explicit programming. In lead identification, ML models are trained on vast datasets comprising chemical structures, biological activities, and other molecular properties^4,5.

2.1.1 Quantitative Structure-Activity Relationship (QSAR) Models:

QSAR models are one of the most established applications of ML in drug discovery. These models correlate the chemical structure of compounds with their biological activity, enabling the prediction of the activity of new compounds based on their molecular features. Traditional QSAR models utilize linear regression or classification algorithms, but recent advancements have integrated more sophisticated ML techniques such as support vector machines (SVM), random forests (RF), and gradient boosting machines (GBM)^6,7

Example: A study by Tropsha and Golbraikh (2007) demonstrated the use of SVM in developing QSAR models that accurately predicted the bioactivity of novel compounds against various biological targets.

2.1.2 Virtual Screening (VS):

Virtual screening is another critical application of ML in lead identification. It involves the computational assessment of large chemical libraries to identify compounds that are most likely to bind to a biological target. VS can be categorized into ligand-based and structure-based approaches:

· Ligand-Based Virtual Screening (LBVS): In LBVS, ML models are trained on known active compounds to predict the activity of new compounds with similar structures⁸.

· Structure-Based Virtual Screening (SBVS): SBVS involves docking simulations, where compounds are virtually "docked" into the active site of a target protein. ML algorithms can refine these docking results by predicting binding affinities based on chemical and structural features^9,10

· Example: A study by Walters and colleagues (2018) used deep learning to enhance VS by predicting binding affinities, leading to the identification of novel inhibitors for a target enzyme.

2.2 Deep Learning in Lead Identification:

Deep learning, a more advanced subset of ML, is particularly effective at modeling complex, non-linear relationships in data. It uses neural networks with multiple layers (hence "deep") to learn from data representations and has proven especially useful in drug discovery^11,12.

2.2.1 Convolutional Neural Networks (CNNs) for Molecular Representation:

CNNs, originally designed for image processing, have been adapted to process molecular graphs and 3D structures. They can capture spatial and chemical features of molecules, making them suitable for tasks like predicting bioactivity, toxicity, and pharmacokinetics¹¹.

Example: Gomes et al. (2017) developed a CNN-based model that predicted the bioactivity of molecules by analyzing their 3D structures, outperforming traditional QSAR models.

2.2.2 Recurrent Neural Networks (RNNs) and Long Short-Term Memory (LSTM) Networks:

RNNs, and their variant LSTMs, are designed to handle sequential data. In drug discovery, they are used to model sequences of molecular substructures, which can help predict the biological activity or generate new molecules¹³.

Example: Segler et al. (2018) employed RNNs to generate novel chemical structures with high binding affinities, demonstrating the potential of DL in de novo drug design.

2.2.3 Generative Models for Drug Design:

Generative models, such as variational autoencoders (VAEs) and generative adversarial networks (GANs), are used to create new molecules with specific properties. These models learn the distribution of chemical spaces and generate novel compounds that are likely to exhibit desired biological activities¹⁴.

Example: Kadurin et al. (2017) used GANs to design molecules with specific pharmacological profiles, showcasing the potential of AI to not only identify but also create promising lead compounds.

2.3 Reinforcement Learning in Lead Optimization:

Reinforcement learning (RL) is a branch of AI where models learn to make sequences of decisions to achieve a specific goal. In drug discovery, RL can be used to optimize lead compounds by iteratively improving their properties through simulated interactions with a target¹⁵.

Example: Popova et al. (2018) applied RL to optimize the molecular properties of lead compounds, achieving significant improvements in their predicted efficacy and safety profiles.

3. Applications of AI in Lead Identification:

AI technologies are transforming various aspects of lead identification, offering solutions to challenges that have long plagued traditional drug discovery methods.

3.1 Predictive Modeling of Bioactivity:

One of the primary applications of AI in lead identification is predictive modeling, where AI algorithms forecast the biological activity of compounds. These models integrate diverse data types, including chemical structures, biological assay results, and pharmacokinetic profiles, to predict critical pharmacological properties such as potency, selectivity, and toxicity¹⁶.

Case Study: In a study by Xu et al. (2020), ML models were used to predict the inhibitory activity of small molecules against a set of kinases, resulting in the identification of several potent inhibitors that were later validated experimentally.

3.2 Drug Repurposing:

Drug repurposing involves finding new therapeutic uses for existing drugs. AI can facilitate this process by identifying patterns and associations in large datasets, uncovering potential repurposing candidates^17,18.

Case Study:

The AI-driven platform developed by Benevolent. AI successfully identified Baricitinib, an already approved drug, as a potential treatment for COVID-19, which was subsequently validated in clinical trials.

3.3 Target Identification and Validation:

AI is also instrumental in identifying and validating new drug targets. By analyzing genetic, proteomic, and clinical data, AI models can predict the likelihood of a target being druggable and its potential role in disease^19,20.

Case Study: IBM Watson for Drug Discovery has been used to analyze vast amounts of biomedical data to identify novel targets for neurodegenerative diseases, offering new avenues for therapeutic development.

3.4 Multi-Objective Optimization:

In lead optimization, it is often necessary to balance multiple objectives, such as efficacy, safety, and pharmacokinetics. AI models can simultaneously optimize these parameters, guiding the modification of lead compounds to achieve a desirable profile^21,22.

Case Study:

Stokes et al. (2020) used an AI model to optimize an antibiotic lead compound, balancing its antibacterial potency with minimal toxicity, leading to the development of a novel antibiotic candidate.

4. Challenges and Limitations:

Despite the significant potential of AI in lead identification, several challenges and limitations must be addressed to fully harness its capabilities.

4.1 Data Quality and Availability:

AI models require large, high-quality datasets for training. However, in drug discovery, access to comprehensive and well-curated data can be limited. Moreover, the variability in experimental conditions and data annotation across different studies can affect the performance of AI models^23,24.

4.2 Model Interpretability:

The "black box" nature of many AI models, particularly deep learning models, poses a challenge in understanding how predictions are made. This lack of interpretability can hinder the acceptance of AI-driven decisions in regulatory environments and among researchers²⁵.

4.3 Computational Resources:

The development and training of AI models, especially deep learning models, require significant computational resources. High-performance computing infrastructure is often needed, which can be a limiting factor for smaller research institutions and startups^26,27.

4.4 Integration with Existing Workflows:

Integrating AI into existing drug discovery workflows requires a shift in both technology and mindset. Traditional methods are deeply entrenched in the industry, and the transition to AI-based approaches may face resistance due to concerns over data handling, model reliability, and the need for skilled personnel to manage AI systems^28,29.

5. Future Directions:

The future of AI in lead identification is promising, with several emerging trends and technologies likely to shape the field.

5.1 Explainable AI:

Making AI models more interpretable and transparent is a crucial area of research. Explainable AI (XAI) aims to provide insights into how AI models make decisions, enabling researchers to understand and trust the predictions made by these models^30,31.

5.2 Integration of Multi-Omics Data:

The integration of multi-omics data, including genomics, proteomics, and metabolomics, will provide a more comprehensive understanding of disease mechanisms and potential drug targets. AI models that can handle and integrate these diverse data types are expected to drive more precise and personalized drug discovery^32,33.

5.3 Collaborative Platforms and Open Science:

AI-driven platforms that facilitate collaboration between academia, industry, and regulatory bodies are likely to accelerate the adoption of AI in drug discovery. Open science initiatives that share data and AI models across the research community will also play a key role in advancing the field^34-40.

5.4 AI for Personalized Medicine:

As AI continues to evolve, its application in personalized medicine is expected to grow. AI can be used to tailor drug discovery and development processes to individual patients, based on their genetic profiles, disease characteristics, and response to treatment^41-45.

6. CONCLUSION:

AI is poised to revolutionize lead identification in drug discovery by enhancing the efficiency, accuracy, and speed of the process. While challenges remain, ongoing advancements in AI technologies and the increasing integration of AI in the pharmaceutical industry suggest a future where AI-driven drug discovery becomes the norm. The continued development of AI methods, coupled with collaborative efforts to overcome existing challenges, will be key to realizing the full potential of AI in drug discovery.

7. REFERENCES:

1. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018; 17(2): 97-113. doi:10.1038/nrd.2017.232.

2. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019; 18(6): 463-477..

3. Mamoshina P, Vieira A, Putin E, Lee J. Applications of deep learning in biomedicine. Mol Pharm. 2018; 15(2): 433-440.

4. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018; 23(6): 1241-1250.

5. Wang L, Zhao S, Zhang Q, Zhang Q. Emerging deep learning methods for drug discovery. Drug Discov Today. 2020; 25(6): 931-940.

6. Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des. 2007; 13(34): 3494-3504.

7. Silverman RB. The Organic Chemistry of Drug Design and Drug Action. Academic Press; 2021. ISBN: 9780128195475.

8. Liu X, Li Y, Wang Y. Advances in ligand-based virtual screening methods and applications. Comput Struct Biotechnol J. 2021; 19: 741-755.

9. Morris GM, Huey R, Lindstrom W, Boas JR, Ouyang H. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16): 2785-2791.

10. Shoichet BK. Virtual screening of chemical libraries. Nat Rev Drug Discov. 2004; 3(4): 321-330.

11. Gómez-Bombarelli R, Noh JM, Mei H. Automatic chemical design using a data-driven continuous representation of molecules. ACS Cent Sci. 2018; 4(2): 268-276.

12. Zhavoronkov A, Aliper A, Artemov A. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019; 37(4): 423-430.

13. Segler MHS, Preuss M, Waller MP. Generating focused molecule libraries for drug discovery with recurrent neural networks. ACS Cent Sci. 2018; 4(1): 120-131.

14. Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. druGAN: An advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. Mol Pharm. 2017; 14(9): 3098-3104.

15. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Sci Adv. 2018; 4(7)

16. Xu Y, Liu J, Li X, Li Y, Sun J, Xia J. Deep learning for drug-induced liver injury. J Chem Inf Model. 2020;60(5):2119-2130.

17. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8): 673-683.

18. Aliper A, Artemov A, Kuznetsov A. Deep learning applications for drug discovery. Mol Inform. 2016; 35(9): 729-740.

19. IBM Watson for Drug Discovery. IBM Watson Health. Available from: https://www.ibm.com/watson-health/learn/drug-discovery.

20. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm. 2016; 13(7): 2524-2530. doi:10.1021/acs.molpharmaceut.6b00248.

21. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz AM, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020; 180(4): 688-702.e13. doi:10.1016/j.cell.2020.01.021.

22. Zhang Q, Li X, Lin J. Reinforcement learning for multi-objective drug optimization. J Chem Inf Model. 2020; 60(10): 4693-4701. doi:10.1021/acs.jcim.0c00893.

23. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019; 18(6): 463-477. doi:10.1038/s41573-019-0024-5.

24. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine. Mol Pharm. 2018; 15(2): 433-440. doi:10.1021/acs.molpharmaceut.7b00360.

25. Ribeiro MT, Singh S, Guestrin C. "Why should I trust you?": Explaining the predictions of any classifier. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2016: 1135-1144. doi:10.1145/2939672.2939778.

26. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018; 23(6): 1241-1250. doi:10.1016/j.drudis.2018.01.039.

27. Wang L, Zhao S, Zhang Q, Zhang Q. Emerging deep learning methods for drug discovery. Drug Discov Today. 2020;25(6):931-940. doi:10.1016/j.drudis.2020.01.019.

28. Walters WP, Murcko M, Guha R. Predictive models for ADME properties. Curr Opin Chem Biol. 2018; 44: 7-14. doi:10.1016/j.cbpa.2018.06.007.

29. Zhang Q, Li X, Lin J. Reinforcement learning for multi-objective drug optimization. J Chem Inf Model. 2020; 60(10): 4693-4701. doi:10.1021/acs.jcim.0c00893.

30. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019; 18(6): 463-477. doi:10.1038/s41573-019-0024-5.

31. Ribeiro MT, Singh S, Guestrin C. "Why should I trust you?": Explaining the predictions of any classifier. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2016: 1135-1144.

32. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021; 596(7873): 583-589.

33. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm. 2016; 13(7): 2524-2530.

34. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz AM, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020; 180(4): 688-702.e13. doi:10.1016/j.cell.2020.01.021.

35. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of deep learning in biomedicine. Mol Pharm. 2018; 15(2): 433-440.

36. Tang B, Wang F, Zhang C. Machine learning for personalized medicine: A review of algorithms and applications. J Pers Med. 2021; 11(6): 527. doi:10.3390/jpm110

37. Manjunatha E, Divekar K, Palaksha MN, Sanglikar G. Synthesis, characterization and evaluation of in-vivo anti-inflammatory activity of some synthesized n-[(3, 5-sub-4, 5-dihydroisoxazol-4-yl) methyl] aniline derivatives. World J Pharm Pharmaceut Sci. 2015; 4(2): 567-78.

38. Manjunatha E, Murugan Vedigounder, Geetha K M, R Nandeesh, Syed Mansoor Ahmed. Isolation, Characterization and In-silico screening of compounds from Ziziphus rugosa bark for their Antiulcer effect. Research Journal of Pharmacy and Technology. 2024; 17(9): 4575-1. doi: 10.52711/0974-360X.2024.00706

39. Kavitha NV, Divekar K, Priyadarshini B, Gajanan S, Manjunath M. Synthesis and antimicrobial activities of some new pyrazole derivatives. Der pharma chemica. 2011; 3(4): 55-62.

40. Prasad Patil, Nripesh Kumar Nrip, Ashok Hajare, Digvijay Hajare, Mahadev K. Patil, Rajesh Kanthe, Anil T. Gaikwad. Artificial Intelligence and Tools in Pharmaceuticals: An Overview. Research Journal of Pharmacy and Technology. 2023; 16(4): 2075-2.

41. Randa Khirfan, Heba Kotb, Huda Atiyeh. Utilizing Artificial Intelligence to Improve Patient Safety: Innovations, Obstacles, and Future Paths. Research Journal of Pharmacy and Technology. 2024; 17(9): 4630-6.

42. Adnan R. Ahmad. Chemical Reaction Prediction using Machine Learning. Research Journal of Pharmacy and Technology. 2024; 17(11): 5435-8.

43. Leo DencelinX, Ramkumar T. Distributed Machine Learning Algorithms to classify Protein secondary structures for Drug Design – A Survey. Research J. Pharm. and Tech. 2017; 10(9): 3173-3180.

44. Yamuna M , Elakkiya A. Review on Mathematical Models in Drug Discovery, Development and Treatments of Various Diseases. Research J. Pharm. and Tech. 2018; 11(1): 407-411.

45. Rajashekar S, Rajukamaraj, Abimanyu S. Risk and Opportunities in Development of New Drug. Research J. Pharm. and Tech. 2020; 13(6): 3041 -3044.

Received on 17.02.2025 Revised on 13.06.2025

Accepted on 30.08.2025 Published on 03.04.2026

Available online from April 06, 2026

Research J. Pharmacy and Technology. 2026;19(4):1914-1918.

DOI: 10.52711/0974-360X.2026.00275

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.